AbbVie (ABBV) 424B5 Prospectus supplement for primary offering

S-3 424B5 EX-FILING FEES 333-284980 0001551152 AbbVie Inc. 0001551152 2025-02-20 2025-02-20 0001551152 1 2025-02-20 2025-02-20 0001551152 2 2025-02-20 2025-02-20 0001551152 3 2025-02-20 2025-02-20 0001551152 4 2025-02-20 2025-02-20 iso4217:USD xbrli:pure xbrli:shares

Calculation of Filing Fee Tables

S-3

AbbVie Inc.

Table 1: Newly Registered and Carry Forward Securities

		Security Type	Security Class Title	Fee Calculation or Carry Forward Rule	Amount Registered	Proposed Maximum Offering Price Per Unit	Maximum Aggregate Offering Price	Fee Rate	Amount of Registration Fee	Carry Forward Form Type	Carry Forward File Number	Carry Forward Initial Effective Date	Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward
Newly Registered Securities
Fees to be Paid	1	Debt	4.650% Notes due 2028	457(r)			$ 1,248,337,500.00	0.0001531	$ 191,120.47
Fees to be Paid	2	Debt	4.875% Notes due 2030	457(r)			$ 999,080,000.00	0.0001531	$ 152,959.15
Fees to be Paid	3	Debt	5.200% Notes due 2035	457(r)			$ 998,570,000.00	0.0001531	$ 152,881.07
Fees to be Paid	4	Debt	5.600% Notes due 2055	457(r)			$ 748,125,000.00	0.0001531	$ 114,537.94
Fees Previously Paid
Carry Forward Securities
Carry Forward Securities
			Total Offering Amounts:				$ 3,994,112,500.00		$ 611,498.63
			Total Fees Previously Paid:						$ 0.00
			Total Fee Offsets:						$ 0.00
			Net Fee Due:						$ 611,498.63

Offering Note

1	Calculated in accordance with the rule 457(r) under the Securities Act of 1933, as amended.
2	Calculated in accordance with the rule 457(r) under the Securities Act of 1933, as amended.
3	Calculated in accordance with the rule 457(r) under the Securities Act of 1933, as amended.
4	Calculated in accordance with the rule 457(r) under the Securities Act of 1933, as amended.

Narrative Disclosure

The maximum aggregate amount of the securities to which the prospectus relates is 3,994,112,500. The prospectus is a final prospectus for the related offering.